Announcements
- Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics
- Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity
- Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024
- Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights
- Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
- Akari Therapeutics Reports First Half 2023 Financial Results and Highlights
- Akari Therapeutics to Present at Emerging Growth Conference
- Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit
- Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs
- Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
More ▼
Key statistics
As of last trade, Akari Therapeutics PLC (CLA:FRA) traded at 1.41, 49.21% above the 52 week low of 0.945 set on Apr 19, 2024.
52-week range
Open | 1.41 |
---|---|
High | 1.41 |
Low | 1.41 |
Bid | 1.36 |
Offer | 1.51 |
Previous close | 1.45 |
Average volume | 0.00 |
---|---|
Shares outstanding | 396.18k |
Free float | -- |
P/E (TTM) | -- |
Market cap | 12.68m USD |
EPS (TTM) | -2.04 USD |
Data delayed at least 15 minutes, as of May 13 2024 07:10 BST.
More ▼